Company CORESTEMCHEMON Inc.

Equities

A166480

KR7166480004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
12,390 ^KRW	+4.56%		+0.41%	+83.01%

Mar. 26	CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI
Mar. 22	CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	CI

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Number of employees: 376

KRW in Million	2022	Weight	2023	Weight	Delta
Non-clinical Laboratory Agency Services 95.1 %	41,284	89.2 %	32,017	95.1 %	-22.45%
Cell Therapy Drugs 4.9 %	5,009	10.8 %	1,640	4.9 %	-67.26%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	46,293	100.0 %	33,657	100.0 %	-27.30%

Managers	Title	Age	Since
Gyeong-Sook Kim CEO	Chief Executive Officer	59	-
Tae-Yong Lee CTO	Chief Tech/Sci/R&D Officer	42	-
Heon-Jeong Lim AUD	Comptroller/Controller/Auditor	56	-
Gil-Ahn Yang SAM	Sales & Marketing	68	18-06-30
Gwang-Soon Kwon PRN	Corporate Officer/Principal	52	17-02-28

Members of the board	Title	Age	Since
Gyeong-Sook Kim CEO	Chief Executive Officer	59	-
Kwan-Hee Hong BRD	Director/Board Member	65	18-02-28
Sang-Bae Han BRD	Director/Board Member	59	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	32,870,376	18,019,956 ( 54.82 %)	10,899,303 ( 33.16 %)	54.82 %

Name	Equities	%	Valuation
CORESTEMCHEMON INC. 23.78 %	7,817,638	23.78 %	68 M ₩
Gyeong-Sook Kim 10.60 %	3,483,320	10.60 %	30 M ₩
Si-Hwan Song 0.8883 %	291,981	0.8883 %	3 M ₩
Gwang-Soon Kwon 0.1436 %	47,200	0.1436 %	408 404 ₩
Byung-chul Kim 0.1284 %	42,200	0.1284 %	365 141 ₩
Jung-Shik Hong 0.0934 %	30,700	0.0934 %	265 636 ₩
Tae-Yong Lee 0.0608 %	20,000	0.0608 %	173 053 ₩
Jeong Wook Hong 0.0304 %	10,000	0.0304 %	86 526 ₩
Jeong In Hong 0.0304 %	10,000	0.0304 %	86 526 ₩
Soon-bok Hong 0.0183 %	6,000	0.0183 %	51 916 ₩

Name	Equities	%	Valuation
CORESTEMCHEMON INC. 23.78%	7,817,638	23.78%	67,643,129 $

CORESTEMCHEMON, Inc.

2/F, I & C Building 24 Pangyo-ro 255 beon-gil

13486, Seongnam-si

http://www.corestem.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CORESTEMCHEMON INC.	+83.01%	197M
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research